New markers in ulcerative colitis.

Area of Science:

• Gastroenterology
• Inflammatory Bowel Disease Research
• Biomarker Discovery

Background:

• Mucosal healing (MH) is a key treatment target in ulcerative colitis (UC), linked to improved long-term outcomes.
• Current UC diagnosis and monitoring rely heavily on colonoscopy, the "gold standard," highlighting the need for non-invasive alternatives.
• Existing non-invasive biomarkers for UC lack sufficient sensitivity and specificity for sole use, necessitating further investigation.

Purpose of the Study:

• To review emerging non-invasive biomarkers for ulcerative colitis (UC).
• To assess the potential of novel markers in correlating with mucosal healing (MH) in UC patients.
• To identify new diagnostic and monitoring tools for UC that could complement or replace invasive procedures.

Main Methods:

• A literature search was conducted using PubMed.
• The review focused on studies published within the last five years.
• Eight potential novel biomarkers for UC were identified and analyzed.

Main Results:

• Eight novel potential biomarkers for UC were identified: trefoil factor 3 (TFF3), leucine-rich Α-2 glycoprotein (LRG), high mobility group box 1 protein (HMGB1), soluble ST2 (sST2), B cell-activating factor (BAFF), annexin A1 (ANXA1), matrix metalloproteinases (MMP), and neutrophil gelatinase-associated lipocalin (NGAL).
• These markers are under investigation for their potential role in assessing intestinal inflammation and mucosal healing in UC.

Conclusions:

• There is a significant need for new, non-invasive markers to improve the diagnosis and monitoring of ulcerative colitis (UC).
• The reviewed novel biomarkers show promise but require further validation to establish their clinical utility in assessing mucosal healing.
• Advancing non-invasive biomarker research in UC could lead to more effective and patient-friendly disease management strategies.